 This study investigated the prognosis of her two positive metastatic breast cancer patients who received Trastuzumab beyond progression and identified predictors of complete response. The results showed that menopausal status, the number of metastatic sites, and use of endocrine therapy with Trastuzumab were associated with complete response. Additionally, the authors noted that these patients may be completely cured with Trastuzumab based therapy. This article was authored by Izet Dogan, Esra Aydin, Lijat Khan Mamadoff, and others.